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Abstract
Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the
deaths secondary to malignancy in humans. Interestingly, this neoplasm has been occasionally
described in companion animals as well. Aim of this study was the preclinical evaluation of the
combination of piroxicam with platinum-based intracavitary chemotherapy in pets. Three
companion animals have been treated in a three years period with this combination. Diagnosis was
obtained by ultrasonographic exam of the body cavities that evidenced thickening of the
mesothelium. A surgical biopsy further substantiated the diagnosis. After drainage of the malignant
effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the
dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose
of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of
0.3 mg/kg. The therapy was able to arrest the effusion in all patients for variable remission times:
one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and
one cat died due to progressive neoplastic growth after six months, when the patient developed a
mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant
effusion secondary to MM in our patients and warrants further investigations.
Introduction
Malignant mesothelioma (MM) is a rare, highly aggressive
tumor, accounting for less than 1% of all cancer deaths in
the world [1]. This neoplasm arises from the surface sero-
sal cells of the pleural (> 90% of cases), peritoneal, and
pericardial cavities and from the tunica vaginalis of the
testis [2]. Several epidemiological and clinicopathological
studies have shown a correlation between exposure to
asbestos and development of pleural mesothelioma [3];
nevertheless, the exact mechanism whereby asbestos
induces the mesothelioma is still unknown [4,5]. Interest-
ingly, recent studies have proposed a role for Simian Virus
40 large T antigen (SV40-Tag) in the pathogenesis of
human mesothelioma, but there are discordant opinions
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in the scientific literature [6-8] Due to the low incidence
of the disease, only few randomized studies have been
performed [reviewed in [9]]. The prognosis is generally
poor with a reported median survival of 4 to 12 months
in either untreated or treated (surgery, radiotherapy, or
chemotherapy) patients [10]. Moreover, mesothelioma
has proven resistant to classical chemotherapeutic and
radiation regimes and the natural history has not been
influenced by standard therapy [11]. Various drugs have
been tested in different combinations so far; among the
most commonly employed are doxorubicin, cyclophos-
phamide, cisplatin (CDDP), carboplatin, gemcitabine,
and pemetrexed [11-15]. Of interest, the combination of
these drugs, with the exception of pemetrexed, does not
appear to provide any clear advantage over mono-therapy
[9]. Therefore, there is need of more effective therapies,
possibly based on the most recent discoveries on the
molecular events involved in mesothelioma pathogenesis
and progression. Our research group has recently demon-
strated that piroxicam, a commonly used NSAID and
COX-inhibitor, has the capability to potentiate the chem-
otherapic effects of cisplatin on mesothelioma cells, both
in vitro and in vivo [16]. This tumor has been infrequently
reported in dogs [17] and even more rarely described in
cats [18-24]. Moreover, treatment has been limited to pal-
liation with corticosteroids or repeated drainage of malig-
nant effusion, or intracavitary platinum coumpounds
[24,25].
A recent study in a mouse model has suggested a potential
synergic action between piroxicam and platinum com-
pounds for the treatment of orthotopic mesothelioma
xenografts [16].
Materials and methods
Privately owned companion animals (two dogs and one
cat) with MM were enrolled to receive the combination of
platinum compounds and piroxicam.
MM was diagnosed by means of ultrasonographic exami-
nation confirmed by histopathologically examination of
biopsy specimens.
Treatment protocol
After tumor biopsy or debulking, dogs received daily
piroxicam at the dose of 0.3 mg/kg PO for 4 months and
CDDP at the dose of 50 mg/m2 every three weeks intra-
peritoneally, for a total of four doses. The patients had a
complete blood cell count, biochemical profile and uri-
nalysis performed 7 days after each chemotherapy. A
ultrasonographic exam was performed on a monthly basis
to check for effusion secondary to malignancy.
The cat was treated with injectable piroxicam, (in order to
better dose the drug), given at the dose of 0.3 mg/kg SC
every other day [26] for 4 months and carboplatin at the
dose of 180 mg/m2 (every 3 weeks) for a total of four
doses. Carboplatin was chosen since systemic administra-
tion of CDDP causes fatal pulmonary edema in cats [26].
The patient had a complete blood cell count, biochemical
profile and urinalysis performed 7 days after each chemo-
therapy. A ultrasonographic exam was performed on a
monthly basis to check for effusion secondary to malig-
nancy.
Results
All the enrolled patients well tolerated the treatment pro-
tocol without significant side effects that were limited to 1
episode of hematochezia in a dog and in the cat, requiring
one week discontinuation of the piroxicam therapy. All
the patients had cavitary effusion at the time of presenta-
tion: abdominal centesis lead to the removal of 180 ml of
fluid as an average. Grossly, the fluid had a yellowish
appearance with pink streaks and with occasional fila-
ments of fibrin, microscopically the sample resulted
highly cellular showed mesothelial cells isolated or gath-
ered to form clusters, with coarse cromatin, presence of
binucleate cells and nuclei of variable size with prominent
and large nucleoli (not shown). Abdominal ultrasonogra-
phy showed thickening of the abdominal serosal surfaces
(not shown). Explorative surgery was performed to per-
form a tumor debulking in a dog and to collect biopsies in
the other patients. Histological examination revealed for
the two dogs a mixed mesothelioma while the cat had an
epithelioid mesothelioma. In figure 1 the histoligical
aspect of the epitheliod mesothelioma of the cat is
depicted. One of the two dogs is still disease free after
debulking and systemic therapy at 2 years, the other dog
and the cat had a reduction of the fluid production by
90% as confirmed by sequential centesis, but developed
progressive disease that let to organ strangulation after 8
and 6 months, respectively. Table 1 summarizes the
patients' characteristics and follow-up.
Discussion
As with humans, pets cannot be cured of MM [17]. As with
humans with down-staged MM at the time of diagnosis,
surgical excision can only be rarely performed in pets [17].
The only exception to this rule may be pericardial MM,
where successful palliation can sometimes be achieved by
total or partial pericardiectomy, relieving the hemody-
namic problems caused by tamponade [27,28]. Systemic
chemotherapy using mitoxantrone or doxorubicin has
been limited to case reports or to small series. Its effective-
ness has been limited when used as single modality, while
its use as an adjunct to cytoreduction (especially pericar-
diectomy) has led to reports of prolonged tumour control
[29-31]. Probably the best use of chemotherapy for canine
mesothelioma is still confined to palliation for advanced
disease by means of intracavitary instillation. ThisJournal of Experimental & Clinical Cancer Research 2008, 27:6 http://www.jeccr.com/content/27/1/6
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approach is well tolerated and is capable of significantly
decrease the amount of fluid released by the mesotheli-
oma, furthermore it seems to induce tumor shrinking for
a limited amount of time. A review of the literature
showed that, in a small cohort of 6 dogs, treatment with
intracavitary cisplatin resulted in survival times approach-
ing one year in 5 patients [25]. Unfortunately the low pen-
etration of the drug within the mesothelial layers (2–3
mm in depth) limits its usefulness in case of bulky dis-
ease. The use of other drugs such as tetracycline, talk, or
bleomycin (Spugnini EP, personal observation) to induce
pleurodesis has been unrewarding [32,33]. Our protocol
showed to be highly tolerable by our patients and proved
to successfully palliate the malignant effusion secondary
to MM in two pets and was capable to induce a long term
control in the third. Interestingly, none of the dogs had
haematological or gastrointestinal toxicities, in particular
vomiting that is one of the limiting factors to the use of
cisplatin in dogs. Also the cat tolerated the therapy with-
out side effects.
In conclusion, considering that there are not established
chemotherapy protocols for pets with MM, the combina-
tion of intracavitary platinum compounds coupled with
piroxicam should be further evaluated, also in view of the
many similarities shared by canine and feline MM with
that of humans. In fact, it has been shown in several
research articles that veterinary cancer patients should be
considered valuable models for the study of novel
approaches such as chemosensitizers, immune modula-
tors, imaging studies and new delivery systems for loco-
regional therapy [34]. However, results should be evalu-
ated with caution since it's likely that MM has a more
benign biological course in dogs than it does in people
and this has to be considered in evaluating uncontrolled
case reports of 1 year survival in the dog.
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